Home / Resources / Antithrombotic drugs and nerve blocks

Guideline summary

Antithrombotic drugs and nerve blocks

What the UK, European and American guidelines say about regional anaesthesia in a patient taking an anticoagulant or antiplatelet drug, set side by side and linked to source.

Draft for clinical sign-off. Compiled 13 November 2026 by Dr Arun Mohanraj FRCA EDRA, Wrightington, Wigan and Leigh NHS Foundation Trust. Every figure is taken from the cited guideline; confirm against the source and your hospital policy before use.

The three guidelines

United Kingdom

Association of Anaesthetists, OAA and RA-UK

2013 · under review by the Association

  • Covers neuraxial and peripheral blocks, and coagulation abnormal from drugs or from disease.1
  • Treats risk as a continuum from normal to very high; an abnormality of coagulation is always a relative contraindication.1
  • Ranks blocks from higher risk to normal risk, and gives separate tables for obstetrics and for trauma, sepsis, uraemia, liver failure and massive transfusion.1

Open the guideline

Europe

ESAIC and ESRA joint guideline

2022

  • Forty statements reached by a Delphi process; certainty of evidence graded C throughout.2
  • Two groups of block: neuraxial and deep blocks, where intervals apply, and superficial compressible blocks, where they do not.2
  • Intervals depend on drug, dose, renal function and a traumatic puncture. Ultrasound, bleeding scores and drug combinations do not shorten them.2

Open the guideline

North America

ASRA Pain Medicine, fifth edition

Published online 2025

  • Replaces the fourth edition of 2018 and reviews the evidence published since.3
  • Consensus statements built on case reports, clinical series, pharmacology and haematology, because spinal haematoma is too rare for a randomised trial.3
  • Drug-by-drug intervals from this edition will be added to the table below once checked line by line against the full text.

Open the guideline

Before the block: minimum time since the last dose

For neuraxial blocks, and for deep blocks in the European guideline. The UK column is the guideline's "acceptable time after drug for block performance".12

DrugUnited Kingdom 2013Europe 2022
Heparins and fondaparinux
Unfractionated heparin, subcutaneous prophylaxis4 h, or normal APTT ratioAt least 4 hLow dose: up to 200 IU/kg/day
Unfractionated heparin, intravenous treatment4 h, or normal APTT ratioIntravenous at least 6 h; subcutaneous high dose at least 12 hAnti-Xa, aPTT or ACT within or below the local normal range
LMWH, prophylactic (low) dose12 hAt least 12 hCreatinine clearance below 30 mL/min: halve the dose or wait 24 h
LMWH, treatment (high) dose24 hAt least 24 hCreatinine clearance below 30 mL/min: halve the dose or wait 48 h. Target anti-Xa 0.1 IU/mL if measured
Fondaparinux, prophylactic (2.5 mg/day)36 to 42 hConsider anti-Xa levelAt least 36 hCreatinine clearance below 50 mL/min: at least 72 h, or reduce to 1.5 mg/day
Fondaparinux, treatment doseAvoidConsider anti-Xa levelNeuraxial block not recommendedIf unavoidable, about 4 days
Vitamin K antagonists
WarfarinINR 1.4 or belowINR in the normal range for the local laboratoryLast dose of warfarin 5 days before
Direct oral anticoagulants
Rivaroxaban, low dose18 hProphylaxis, creatinine clearance above 30 mL/min24 h30 h if creatinine clearance below 30 mL/min
Rivaroxaban, high dose48 hTreatment, creatinine clearance above 30 mL/minAt least 72 hOr a calibrated drug level below 30 ng/mL
Apixaban, low dose24 to 48 hProphylaxis36 h
Apixaban, high doseNot listedAt least 72 hOr a calibrated drug level below 30 ng/mL
EdoxabanNot listedLow dose 24 h (30 h if creatinine clearance below 30 mL/min); high dose at least 72 h
Dabigatran48 h if creatinine clearance above 80 mL/min72 h at 50 to 80; 96 h at 30 to 50Low dose 48 h; high dose at least 72 hOr normal thrombin time, or level below 30 ng/mL
Antiplatelet drugs
AspirinNo additional precautionsLow dose (under 200 mg/day): no intervalHigh dose: 3 to 7 days
NSAIDsNo additional precautionsNot covered
Clopidogrel7 days5 to 7 days
Prasugrel7 days7 days
Ticagrelor5 daysAt least 5 days
Others
Thrombolytic drugs10 daysNot covered
The European guideline defines low and high dose for each drug, for example enoxaparin 40 mg a day or less as low-dose LMWH. Where two drugs are combined, it uses the longer interval.2

After the block or catheter removal: time to the next dose

DrugUnited Kingdom 2013Europe 2022
Unfractionated heparinSubcutaneous prophylaxis 1 h; intravenous treatment 4 hAt the time set by thromboprophylaxis or treatment guidance
LMWH4 hTreatment dose: consider 24 h after a traumatic blockAt the time set by thromboprophylaxis or treatment guidanceHigh dose only after the catheter is out
FondaparinuxProphylaxis 6 to 12 h; treatment 12 hAt the time set by thromboprophylaxis guidance
Rivaroxaban, apixaban, dabigatran6 hAt the time set by thromboprophylaxis or treatment guidance
Clopidogrel, prasugrel, ticagrelor6 hClopidogrel 75 mg without delay; prasugrel or ticagrelor at least 24 h; clopidogrel 300 mg at least 2 days
AspirinNo additional precautionsLow dose at the next routine time; high dose at least 6 h
Thrombolytic drugs10 daysNot covered

After a bloody tap, the European guideline allows the interval to the next dose to be extended by joint decision.2 With a neuraxial catheter in place, the UK guideline advises caution with prophylactic heparins and does not recommend treatment-dose LMWH, the oral anticoagulants or the P2Y12 inhibitors.1

Which block carries which risk (UK)

The UK guideline orders blocks by relative risk in a patient with abnormal coagulation.1

Higher riskEpidural with catheter, single-shot epidural, spinal
Paravertebral blocksParavertebral, lumbar plexus, lumbar sympathectomy, deep cervical plexus
Deep blocksCoeliac plexus, stellate ganglion, proximal sciatic, obturator, infraclavicular and supraclavicular brachial plexus
Superficial perivascular blocksPopliteal sciatic, femoral, intercostal, interscalene and axillary brachial plexus
Fascial blocksIlio-inguinal, ilio-hypogastric, transversus abdominis plane, fascia lata
Superficial blocksForearm nerves, saphenous at the knee, ankle, superficial cervical plexus, wrist, digital nerve, Bier's block
Normal riskLocal infiltration

Deep and superficial (Europe)

Deep: intervals apply

Neuraxial blocks, and deep blocks such as stellate ganglion, deep cervical plexus, cervical and thoracic paravertebral, infraclavicular, lumbar plexus, quadratus lumborum, sacral plexus, pericapsular nerve group and proximal sciatic.2

Superficial: intervals do not apply

Superficial, compressible blocks may be performed in patients taking a vitamin K antagonist, a direct oral anticoagulant, heparin or fondaparinux at any dose, and with antiplatelet drugs after a risk-benefit assessment.2

After any neuraxial or deep block

Neurological checks for at least 24 hours. If a haematoma is suspected: immediate imaging, MRI preferred, and decompression within 6 hours if indicated.2

Platelets and INR in the UK guideline

INR 1.4 or below

The threshold for neuraxial block in a patient taking warfarin.1

Platelets above 75 × 10⁹/L

Proposed as adequate for regional blocks when there are no other risk factors and the count is not falling. The guideline stresses that thresholds are not binary.1

0.85 per 100,000

Vertebral canal haematoma after neuraxial block in the Third National Audit Project, as quoted by the guideline.1

Other societies

Society or regionDocumentPosition
Scandinavia (SSAI)Endorsement, 20225Endorses the ESAIC/ESRA guideline
CanadaPractice advisory, 20196Bleeding risk of peripheral nerve and interfascial plane blocks
Obstetric anaesthesia (SOAP, United States)Consensus statement, 20187Pregnant and postpartum women receiving thromboprophylaxis or higher-dose anticoagulants
Brazil (SBA)Guideline update, 20208National regional anaesthesia guideline for patients taking anticoagulants
AfricaNo AFSRA guideline identifiedThe South African Society of Anaesthesiologists regional anaesthesia guideline of 2016 bases its anticoagulation section on the ASRA guideline9
Asia and OceaniaNo AOSRA-PM guideline identifiedSearched 13 November 2026

The European guideline authors have published additional comments on their 2022 document.4

In practice

Three questions before the block

  • Is the target neuraxial or deep and non-compressible, or superficial and compressible?
  • Which drug, what dose, and when was the last one taken?
  • What is the renal function?
How this page was compiled

Sources and search

PubMed was searched on 13 November 2026 for society guidelines on regional anaesthesia and antithrombotic drugs. Figures in the tables were read from the full text of the UK and European guidelines.

Local WWL anticoagulation policy link to be added.

References

  1. Association of Anaesthetists of Great Britain and Ireland, Obstetric Anaesthetists' Association, Regional Anaesthesia UK. Regional anaesthesia and patients with abnormalities of coagulation. Anaesthesia 2013; 68: 966-72. Guideline
    https://doi.org/10.1111/anae.12359
  2. Kietaibl S, Ferrandis R, Godier A, et al. Regional anaesthesia in patients on antithrombotic drugs: joint ESAIC/ESRA guidelines. Eur J Anaesthesiol 2022; 39: 100-32. Guideline
    https://doi.org/10.1097/EJA.0000000000001600
  3. Kopp SL, Vandermeulen E, McBane RD, Perlas A, Leffert L, Horlocker T. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fifth edition). Reg Anesth Pain Med 2026; 51: 1233-61 (published online January 2025). Guideline
    https://doi.org/10.1136/rapm-2024-105766
  4. Vandermeulen E, Schlimp CJ, Kietaibl S. Additional comments on the 2022 Joint ESAIC/ESRA guidelines: regional anaesthesia in patients on antithrombotic drugs. Eur J Anaesthesiol 2023; 40: 68-70. Commentary
    https://doi.org/10.1097/EJA.0000000000001732
  5. Møller MH, Sigurðsson MI, Olkkola KT, et al. Regional anaesthesia in patients on antithrombotic drugs - a joint ESAIC/ESRA guideline: Endorsement by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand 2022; 66: 887-889. Endorsement
    https://doi.org/10.1111/aas.14093
  6. Tsui BCH, Kirkham K, Kwofie MK, et al. Practice advisory on the bleeding risks for peripheral nerve and interfascial plane blockade: evidence review and expert consensus. Can J Anaesth 2019; 66: 1356-1384. Practice advisory
    https://doi.org/10.1007/s12630-019-01466-w
  7. Leffert L, Butwick A, Carvalho B, et al. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants. Anesth Analg 2018; 126: 928-944. Consensus statement
    https://doi.org/10.1213/ANE.0000000000002530
  8. Fonseca NM, Pontes JPJ, Perez MV, et al. [SBA 2020: Regional anesthesia guideline for using anticoagulants update]. Braz J Anesthesiol 2020; 70: 364-387. Guideline
    https://doi.org/10.1016/j.bjan.2020.02.006
  9. Laäs DJ, Naidoo M. Perioperative antithrombotic medication: an approach for the primary care clinician. Afr J Prim Health Care Fam Med 2024; 16: a4555. Review
    https://doi.org/10.4102/phcfm.v16i1.4555